New Lantern secures $19M to advance radiology automation, streamlining tasks and boosting radiologists’ productivity with cloud-based AI solutions.
A San Francisco technology firm known as New Lantern has attracted $19 million in Series A capital from Benchmark and other investors including Afore Capital and Anthology Fund. The funding aids in its goal to advance radiology operational solutions to drive out wastage and increase effectiveness for radiologists concentrating on interpretation work.
Overcoming Radiology’s Time-Taking Puzzles:
Radiologists spend much of their shift, about eight hours, measuring and reporting. However, New Lantern aims to automate 25% of these tasks, with plans to expand this to 90%. Furthermore, inspired by his mother’s experience in radiology, Shiva Suri founded the firm to apply technology that improves workflow while ensuring radiologists remain central to the process.
Cloud-Native Radiology Suite:
New Lantern is the first cloud-native AI radiology suite in that it is easier and quicker to implement, update, and expand. It provides a PACS replacement, with new-age convenience by automating tasks as basic as 3D measurements, to report preparation.
Related Content: AI Radiology Efficiency boosted as mediaire secures €12M
By handling ordinary tasks, New Lantern enhances the satisfaction of radiologists, thereby reducing the rate of burnout, and, therefore, the time it takes to serve patients. Earlier diagnosis matters in crises, as faster problem identification speeds up patient treatment.
Challenges and Future Outlook:
However, New Lantern has several challenges, including, but not limited to data privacy, change resistance, and regulatory environments. However, its adoption of that approach, partnering with radiologists as part of the team rather than competing against them, sets it up as a possible disruptor in the radiology AI market competition.
After taking $19M and promising to bring innovation, New Lantern is ready to become a trailblazer in healthcare AI by optimizing the processes on the clinical side.
